Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cancel the denosumab holiday.

Literature DB >> 26932443

Cancel the denosumab holiday.

M R McClung¹.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2016 PMID： 26932443 DOI： 10.1007/s00198-016-3553-3

Source DB: PubMed Journal: Osteoporos Int ISSN： 0937-941X Impact factor: 4.507

× No keyword cloud information.

56 in total

1. Bone turnover in postmenopausal women after withdrawal of estrogen/gestagen replacement therapy.

Authors: K Thomsen; B J Riis; J S Johansen; C Christiansen; P Rødbro
Journal: Gynecol Endocrinol Date: 1987-06 Impact factor: 2.260

2. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI.

Authors:
Journal: JAMA Date: 1996-11-06 Impact factor: 56.272

3. Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics.

Authors: A W Popp; P K Zysset; K Lippuner
Journal: Osteoporos Int Date: 2015-12-22 Impact factor: 4.507

4. Discontinuation of long term clopidogrel therapy induces platelet rebound hyperaggregability between 2 and 6 weeks post cessation.

Authors: Philipp Diehl; Christoph Halscheid; Christoph Olivier; Thomas Helbing; Christoph Bode; Martin Moser
Journal: Clin Res Cardiol Date: 2011-04-09 Impact factor: 5.460

5. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial.

Authors: Jane A Cauley; John Robbins; Zhao Chen; Steven R Cummings; Rebecca D Jackson; Andrea Z LaCroix; Meryl LeBoff; Cora E Lewis; Joan McGowan; Joan Neuner; Mary Pettinger; Marcia L Stefanick; Jean Wactawski-Wende; Nelson B Watts
Journal: JAMA Date: 2003-10-01 Impact factor: 56.272

6. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.

Authors: Robert Lindsay; Wim H Scheele; Robert Neer; Gerhardt Pohl; Silvano Adami; Carlos Mautalen; Jean-Yves Reginster; Jan J Stepan; Stephen L Myers; Bruce H Mitlak
Journal: Arch Intern Med Date: 2004-10-11

7. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial.

Authors: Paul D Miller; Michael A Bolognese; E Michael Lewiecki; Michael R McClung; Beiying Ding; Matthew Austin; Yu Liu; Javier San Martin
Journal: Bone Date: 2008-04-26 Impact factor: 4.398

8. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin.

Authors: Gerardo Heiss; Robert Wallace; Garnet L Anderson; Aaron Aragaki; Shirley A A Beresford; Robert Brzyski; Rowan T Chlebowski; Margery Gass; Andrea LaCroix; JoAnn E Manson; Ross L Prentice; Jacques Rossouw; Marcia L Stefanick
Journal: JAMA Date: 2008-03-05 Impact factor: 56.272

9. Changes in bone density and turnover after alendronate or estrogen withdrawal.

Authors: Richard D Wasnich; Yu Z Bagger; David J Hosking; Michael R McClung; Mei Wu; Ann Marie Mantz; John J Yates; Philip D Ross; Peter Alexandersen; Pernille Ravn; Claus Christiansen; Arthur C Santora
Journal: Menopause Date: 2004 Nov-Dec Impact factor: 2.953

10. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.

Authors: S Papapoulos; K Lippuner; C Roux; C J F Lin; D L Kendler; E M Lewiecki; M L Brandi; E Czerwiński; E Franek; P Lakatos; C Mautalen; S Minisola; J Y Reginster; S Jensen; N S Daizadeh; A Wang; M Gavin; C Libanati; R B Wagman; H G Bone
Journal: Osteoporos Int Date: 2015-07-23 Impact factor: 4.507

16 in total

Review 1. Using Osteoporosis Therapies in Combination.

Authors: Michael R McClung
Journal: Curr Osteoporos Rep Date: 2017-08 Impact factor: 5.096

2. Denosumab-related osteonecrosis of the jaw after tooth extraction and the effects of a short drug holiday in cancer patients: a multicenter retrospective study.

Authors: T Hasegawa; N Ueda; S I Yamada; S Kato; E Iwata; S Hayashida; Y Kojima; M Shinohara; I Tojo; H Nakahara; T Yamaguchi; T Kirita; H Kurita; Y Shibuya; S Soutome; M Akashi
Journal: Osteoporos Int Date: 2021-05-17 Impact factor: 4.507

Review 3. [Antibodies as treatment option in older adults].

Authors: M Gosch; S Wicklein
Journal: Z Gerontol Geriatr Date: 2017-12-20 Impact factor: 1.281

4. Adrenal crisis after first infusion of zoledronic acid: a case report.

Authors: M Smrecnik; Z Kavcic Trsinar; T Kocjan
Journal: Osteoporos Int Date: 2018-03-28 Impact factor: 4.507

5. Rebound-associated vertebral fractures after discontinuation of denosumab for the treatment of maxillitis.

Authors: R Niimi; T Kono; A Nishihara; M Hasegawa; T Kono; A Sudo
Journal: Osteoporos Int Date: 2017-12-11 Impact factor: 4.507

6. Long-term persistence in patients with osteoporosis receiving denosumab in routine practice: 36-month non-interventional, observational study.

Authors: D M Borek; R C Smith; C N Gruber; B L Gruber
Journal: Osteoporos Int Date: 2019-04-22 Impact factor: 4.507

Review 7. Osteoporosis: Treat-to-Target.

Authors: E Michael Lewiecki
Journal: Curr Osteoporos Rep Date: 2017-04 Impact factor: 5.096